Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (DE:6MK)
XETRA:6MK
Holding DE:6MK?
Track your performance easily
6MK Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€90.60 - €125.60
Previous Close€94.6
Volume23.00
Average Volume (3M)2.13K
Market Cap
€237.34B
Enterprise Value€261.83B
Total Cash (Recent Filing)$11.35B
Total Debt (Recent Filing)$37.79B
Price to Earnings (P/E)21.4
Beta0.11
Next Earnings
Feb 04, 2025EPS Estimate
€1.73Last Dividend Ex-Date
Sep 16, 2024Dividend Yield3.01%
Share Statistics
EPS (TTM)4.40
Shares Outstanding2,534,809,312
10 Day Avg. Volume1,911
30 Day Avg. Volume2,131
Standard Deviation0.06
R-Squared0.05
Alpha0.00803
Financial Highlights & Ratios
Price to Book (P/B)1.51
Price to Sales (P/S)4.15
Price to Cash Flow (P/CF)11.50
P/FCF Ratio13.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.19
Enterprise Value/Gross Profit5.95
Enterprise Value/Ebitda13.46
Forecast
1Y Price Target
€122.57Price Target Upside29.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Merck & Company News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMerck could still meet the $16.5 billion topline expectation due to Keytruda strength and Winrevair upside.
Product DevelopmentClesrovimab's advantages, including clinical differentiation and single dose, are expected to help it compete globally.
Product GrowthWinrevair remains a bright spot with organic demand driving uptake.
Bears Say
Financial Performance PressureKeytruda patent expiration in 2028 pressures future forecasts.
Gardasil Sales ChallengesGardasil in China will remain an overhang for Merck through 2025.
Keytruda CompetitionCompetitor Summit Therapeutics presented detailed data from their HARMONi-2 Phase 3 trial in PD-L1 positive NSCLC showing a statistically significant median PFS benefit compared to MRK's Keytruda.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.04% Insiders
21.29% Mutual Funds
3.70% Other Institutional Investors
54.48% Public Companies and
Individual Investors
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €90.60 and its highest was €125.60 in the past 12 months.
What is Merck & Company’s market cap?
Currently, no data Available
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Feb 04, 2025 which is in 94 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Oct 31, 2024. The company reported €1.451 earnings per share for the quarter, beating the consensus estimate of €1.371 by €0.079.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of €0.71 which represents an annual dividend yield of 3.01%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is €1.73.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,534,809,300 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of €1.451 in its last earnings report, beating expectations of €1.371. Following the earnings report the stock price went down -1.569%.
Which hedge fund is a major shareholder of Merck & Company?
Among the largest hedge funds holding Merck & Company’s share is Fisher Asset Management LLC. It holds Merck & Company’s shares valued at 2B.
---
Merck & Company Stock Smart Score
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
6MK Company Deck
---
6MK Earnings Call
Q3 2024
0:00 / 0:00
---
6MK Sales Breakdown
45.91% Oncology
22.09% Vaccines
5.64% Hospital Acute Care
5.60% Diabetes
20.75% Other
---
6MK Stock 12 Month Forecast
Average Price Target
€122.57
▲(29.57% Upside)
Technical Analysis
Best Analysts Covering 6MK
1 Year
1 Year Success Rate
15/27 ratings generated profit
1 Year Average Return
+4.94%
assigned a buy rating 9 days ago
Copying Carter Gould's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +4.94% per trade.
---